CalciMedica Bolsters Board with Appointment of Dr. Alan Glicklich
Generado por agente de IAMarcus Lee
martes, 14 de enero de 2025, 7:13 am ET1 min de lectura
CALC--
CalciMedica, Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, has announced the appointment of Dr. Alan Glicklich to its Board of Directors, effective January 15, 2025. Dr. Glicklich, currently serving as Chief Medical Officer of Nuvig Therapeutics, brings over 20 years of biotechnology industry experience to CalciMedica, with a strong background in inflammatory and immunologic disease spaces.
Dr. Glicklich's extensive experience in clinical development, including leadership roles at Chinook Therapeutics, Bird Rock Bio, and Arena Pharmaceuticals, will be invaluable to CalciMedica as it progresses its lead product candidate, Auxora, towards Phase 3 trials in acute pancreatitis and awaits data from the KOURAGE trial in acute kidney injury. His expertise in inflammatory and immunologic diseases will also contribute to CalciMedica's ongoing clinical trials and pipeline development.
Dr. Glicklich's appointment strengthens CalciMedica's expertise in inflammatory and immunologic disease spaces, which will be crucial in advancing Auxora and other potential therapies through clinical trials and towards regulatory approval. His leadership and strategic guidance will be instrumental in CalciMedica's future drug development strategies, ensuring that the company remains at the forefront of innovative therapies for life-threatening inflammatory and immunologic diseases.
In conclusion, CalciMedica's appointment of Dr. Alan Glicklich to its Board of Directors is a strategic move that will significantly contribute to the company's ongoing clinical trials and pipeline development. Dr. Glicklich's expertise in inflammatory and immunologic diseases, coupled with his leadership in clinical development, will be invaluable in advancing CalciMedica's mission to develop therapies for critically ill patients whose needs are unmet by current therapies.
CHRO--
CalciMedica, Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, has announced the appointment of Dr. Alan Glicklich to its Board of Directors, effective January 15, 2025. Dr. Glicklich, currently serving as Chief Medical Officer of Nuvig Therapeutics, brings over 20 years of biotechnology industry experience to CalciMedica, with a strong background in inflammatory and immunologic disease spaces.
Dr. Glicklich's extensive experience in clinical development, including leadership roles at Chinook Therapeutics, Bird Rock Bio, and Arena Pharmaceuticals, will be invaluable to CalciMedica as it progresses its lead product candidate, Auxora, towards Phase 3 trials in acute pancreatitis and awaits data from the KOURAGE trial in acute kidney injury. His expertise in inflammatory and immunologic diseases will also contribute to CalciMedica's ongoing clinical trials and pipeline development.
Dr. Glicklich's appointment strengthens CalciMedica's expertise in inflammatory and immunologic disease spaces, which will be crucial in advancing Auxora and other potential therapies through clinical trials and towards regulatory approval. His leadership and strategic guidance will be instrumental in CalciMedica's future drug development strategies, ensuring that the company remains at the forefront of innovative therapies for life-threatening inflammatory and immunologic diseases.
In conclusion, CalciMedica's appointment of Dr. Alan Glicklich to its Board of Directors is a strategic move that will significantly contribute to the company's ongoing clinical trials and pipeline development. Dr. Glicklich's expertise in inflammatory and immunologic diseases, coupled with his leadership in clinical development, will be invaluable in advancing CalciMedica's mission to develop therapies for critically ill patients whose needs are unmet by current therapies.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios